Peptide Straight Talk · Flash · September 29, 2026 · Educational only, not medical advice
The buzz just met the paper
If you follow the weight-loss and peptide space, retatrutide is the name that keeps coming up. Today it cleared a big bar: full phase 3 results from the TRIUMPH-2 trial are now published and peer reviewed in The Lancet. It's among the first peer-reviewed phase 3 obesity results for a triple-agonist drug, and it's a moment a lot of people have been waiting for.
What the study found
TRIUMPH-2 enrolled 1,152 adults at 92 sites in 8 countries. Everyone had type 2 diabetes plus overweight or obesity (a body mass index, or BMI, of 27 or higher). On average, participants started with a BMI of 38.2 and an A1c (a roughly three-month average of blood sugar) of 7.71%, and had lived with obesity for a median of 21 years.
After 80 weeks, people on retatrutide lost up to 18.8% of their body weight on average across doses, compared with 5.1% on placebo (a dummy treatment). Every dose beat placebo by a wide statistical margin. The paper also reports better blood-sugar control.
Why 18.8% and not July's 20.8%?
Both numbers are real. They answer different questions.
20.8% (Lilly's July 23 topline announcement) used the efficacy estimand. Lilly defines it as the result "had all randomized participants remained on study intervention." In other words, it estimates what happens if everyone stays on the drug.
18.8% (the paper's headline) uses the treatment-regimen estimand. It counts everyone who was randomized, including people who stopped treatment along the way.
The second is the more conservative, real-world-leaning number, and it's the one the peer-reviewed paper leads with. So that's the one we use.
Why people think it works
Retatrutide is a triple agonist: one molecule that switches on three hormone receptors.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are gut hormones involved in appetite, fullness, and blood-sugar control. They're the same pathways used by today's approved weight-loss medicines semaglutide (GLP-1) and tirzepatide (GLP-1 plus GIP).
Glucagon is the third lever. Researchers think adding it may increase how much energy the body uses and help with liver fat.
That three-pathway design is the scientific reason for all the excitement, and TRIUMPH-2 is peer-reviewed evidence that the idea translates into large weight loss in people living with type 2 diabetes.
Side effects and who paid
Eli Lilly, the company developing retatrutide, funded the trial.
The most common side effects were digestive:
Diarrhea: 27–34% on retatrutide vs 13% on placebo
Nausea: 14–28% vs 8%
Also reported:
Low blood pressure (hypotension): 1–6% vs under 1%
Dysesthesia, meaning unusual skin sensations such as tingling or burning: 4–7% vs 1%
Stopping treatment because of side effects (or death) ranged from 4% to 12% on retatrutide vs 5% on placebo. It was highest in the middle-dose group, so it didn't simply rise with dose. There were six deaths on retatrutide and one on placebo; investigators judged none of them related to the study drug. The authors describe the overall safety profile as consistent with the GLP-1 drug class.
What's still open
Who was studied. Everyone in TRIUMPH-2 had type 2 diabetes. This paper doesn't directly tell us how retatrutide performs in people without it.
How long. Eighty weeks is a solid run, but longer-term results, and what happens after people stop, aren't answered here.
Who's checking. It's a company-funded trial. Independent replication and more real-world data will add confidence.
Rare events. Death counts were small and judged unrelated, but bigger and longer datasets are how rare safety signals get settled.
None of these are knocks on the result. They're the next questions.
A study is not access
Retatrutide is investigational. It is not FDA-approved (FDA is the U.S. Food and Drug Administration). Lilly expects to file for U.S. approval in the first quarter of 2027. A published trial is a big step on that road, but it doesn't make the drug available. Anything sold online under the name "retatrutide" is unapproved.
Coming up next
Our next issue is the BPC-157 deep dive: what people claim, what the science supports, and where FDA and compounding fit in.
Sources
The Lancet (published Sep 29, 2026). "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2)." Phase 3 randomized controlled trial. DOI: 10.1016/S0140-6736(26)01861-1. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/abstract
ClinicalTrials.gov, NCT05929079 (TRIUMPH-2 registry record).
Eli Lilly (July 23, 2026). Topline release, "TRIUMPH-2 Efficacy Estimand Results" (20.8%; efficacy estimand defined as "had all randomized participants remained on study intervention"). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Educational content only. Nothing here is medical advice or a recommendation to use any product.